Přejít k obsahu
Merck
Všechny fotografie(3)

Key Documents

WH0008658M1

Sigma-Aldrich

Monoclonal Anti-TNKS antibody produced in mouse

clone 1A2, purified immunoglobulin, buffered aqueous solution

Synonyma:

Anti-PARP5A, Anti-PARP5a, Anti-PARPL, Anti-TIN1, Anti-TINF1, Anti-TNKS1, Anti-tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(3)

About This Item

MDL number:
MFCD02686643
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

1A2, monoclonal

form

buffered aqueous solution

species reactivity

human

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
indirect ELISA: suitable
western blot: 1-5 μg/mL

isotype

IgG2aκ

GenBank accession no.

NM_003747

UniProt accession no.

O95271

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... TNKS(8658)

General description

The gene TNKS (tankyrase) is mapped to human chromosome 8p23.1. It belongs to the PARP (poly (ADP-ribose) polymerase) family of proteins and is responsible for addition of poly (ADP-ribose) (PAR) to substrate proteins. The TNKS protein contains ankyrin repeats and a sterile α-motif (SAM).

Immunogen

TNKS (NP_003738, 1017 a.a. ~ 1124 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Sequence
TERKEGEVAGLDMNISQFLKSLGLEHLRDIFETEQITLDVLADMGHEELKEIGINAYGHRHKLIKGVERLLGGQQGTNPYLTFHCVNQGTILLDLAPEDKEYQSVEEE

Biochem/physiol Actions

TNKS (tankyrase) is a regulator of Wnt-signaling. It negatively regulates Axin1, thereby suppressing β-catenin degradation and causing hyperactivation of Wnt/β-catenin signaling. TNKS controls cell death and telomere length. It might also be associated with osteoarthritis. In murine lung cancer model, silencing of this gene reduces lung cancer cell growth. Application of TNKS inhibitor suppresses growth of hepatocellular carcinoma cells. Absence of TNKS activity helps in replication of human cytomegalovirus (HCMV).

Physical form

Solution in phosphate buffered saline, pH 7.4

Legal Information

GenBank is a registered trademark of United States Department of Health and Human Services

Ještě jste nenalezli správný produkt?  

Vyzkoušejte náš produkt Nástroj pro výběr produktů.

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)

Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Genetic variants in eleven telomere-associated genes and the risk of incident cardio/cerebrovascular disease: The Women's Genome Health Study.
Zee RY, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 412, 199-202 (2011)
Tankyrase inhibitors attenuate WNT/?-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L, et al.
Oncotarget, 6, 25390-25401 (2015)
A genome-wide association study of copy-number variation identifies putative loci associated with osteoarthritis in Koreans.
Moon S, et al.
BMC Musculoskelet. Disord., 16, 76-76 (2015)
Tankyrase 1 polymorphism associated with an increased risk in developing non-small cell lung cancer in a Chinese population: a proof-of-principle study.
Wang Y, et al.
International Journal of Clinical and Experimental Pathology, 8, 10500-10511 (2015)
Sharon McGonigle et al.
Oncotarget, 6(38), 41307-41323 (2015-10-30)
Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment. Here, we describe the development of the novel PARP inhibitor E7449, a potent PARP1/2
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.